Juventas' regenerative ischemia therapy moves forward
This article was originally published in Scrip
Executive Summary
Juventas Therapeutics' lead candidate JVS-100, a regenerative therapy for critical limb ischemia, has met its Phase II primary endpoints for safety and shown some hints of efficacy, the private US firm announced at the American Heart Association meeting in Chicago this week.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.